In addition to common EGFR activation mutations, targets such as ALK rearrangement, ROS1 rearrangement, RET rearrangement, BRAF V600E, MET exon 14 skip mutation, KRAS G12C, etc. have been gradually approved for targeted drug application in advanced non-small cell lung cancer (6, 18). This evidence concerns the gene BRAF and non-small cell lung carcinoma.